

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

RECEIVED
SECRETARY OF THE SENATE
PUBLIC RECORDS

02 FEB 14 10 21 AM '02

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) -All Filers Are Required to Complete This Page

1. Registrant Name Bristol-Myers Squibb Company			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address 655 15th St., NW City Washington, DC State/Zip (or Country) 20005 USA			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name Richard Thompson	Telephone (202) 783-0900	E-mail (optional)	5. Senate ID # 7053-12
7. Client Name <input checked="" type="checkbox"/> Self			6. House ID # 7053

TYPE OF REPORT 8. Year 2001 Midyear (January 1-June 30) OR Year End (July 1-Dec

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report >> Termination Date _____

11. No Lobbyi

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Income (nearest \$20,000)	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$2,400,000.00</u> Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of: <input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definiti <input type="checkbox"/> Method B. Reporting amounts under section 6033 the Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162(e Internal Revenue Code

Signature



Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ADV (one per page)

16. Specific Lobbying issues

H.R.2352, Fair Balance Prescription Drug Advertisement Act of 2001, Lobbied to ensure that any proposed did not inadvertently impede the consumers access to accurate information about pharmaceutical products.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific Lobbying issues
H.CON.RES.83, Establishing the congressional budget for the United States Government for fiscal year 2002 congressional budget for the United States Government for fiscal year 2001, and setting forth appropriate budget levels for each of fiscal years 2001 and 2002,
H.R.2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2002, Lobbied for increased patient safety requirements.
H.R.3061, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2002, Lobbied in support of funding for Ryan White AIDS program.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CAW (one per page)

16. Specific Lobbying issues
No activity.

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific Lobbying issues

**H.R.1862, Greater Access to Affordable Pharmaceuticals Act of 2001, Lobbied for improvements to Hatch-V
H.R.1866, To amend title 35, United States Code, to clarify the basis for granting requests for reexamination
Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.**

H.R.1886, To amend title 35, United States Code, to provide for appeals by third parties in certain patent reexamination proceedings., Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical intellectual property rights.

H.R.2047, Patent and Trademark Office Authorization Act of 2002, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.

H.R.2887, Best Pharmaceuticals for Children Act, Lobbied to preserve incentives for improved medicines for S.1789, Best Pharmaceuticals for Children Act, Lobbied to preserve incentives for improved medicines for children.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	
Ryan, John	
Thompson, Richard	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.740, Patent and Trademark Office Reauthorization Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.741, Madrid Protocol Implementation Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.933, Affordable HIV/AIDS Medicines for Poor Countries Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.197, Spyware Control and Privacy Protection Act of 2001, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.290, Student Privacy Protection Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.30, Financial Information Privacy Protection Act of 2001, Lobbied to ensure any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.320, Intellectual Property and High Technology Technical Amendments Act of 2001, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.463, Global Access to AIDS Treatment Act of 2001, Lobbied to ensure that proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.6, Patients' Bill of Rights Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.812, Greater Access to Affordable Pharmaceuticals Act of 2001, Lobbied for improvements to Hatch-Waxman law
16	Lobbying Issues	S.838, Best Pharmaceuticals for Children Act, Lobbied to preserve incentives for improved medicines for children.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CSP (one per page)

16. Specific Lobbying issues

H.R.113, Wireless Telephone Spam Protection Act, Lobbied to ensure that any proposed privacy protections inadvertently restrict the use of protected clinical data in pharmaceutical research.

H.R.1786, To impose tariff-rate quotas on certain casein and milk protein concentrates., Lobbied to ensure that proposed tariffs did not inadvertently impede the legitimate importation of caseins for use in baby formulas.

H.R.2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2002, Lobbied for increased patient safety requirements.

H.R.2352, Fair Balance Prescription Drug Advertisement Act of 2001, Lobbied to ensure that any proposed regulations did not inadvertently impede the consumers access to accurate information about pharmaceutical products.

H.R.237, Consumer Internet Privacy Enhancement Act, Lobbied to ensure that any proposed privacy protections inadvertently restrict the use of protected clinical data in pharmaceutical research.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.2500, Departments of Commerce, Justice, and State, the Judiciary and Related Agencies Appropriations Act, 2002., Lobbied to ensure that any proposed restrictions on methamphetamine production did not inadvertently impede the use of ephedrine in over-the-counter (OTC) allergy pharmaceuticals.
16	Lobbying Issues	H.R.260, Wireless Privacy Protection Act of 2001, Lobbied to ensure that any proposed privacy protections did not inadvertently restrict the use of protected clinical data in pharmaceutical research.
16	Lobbying Issues	H.R.602, Genetic Nondiscrimination in Health Insurance and Employment Act, Lobbied to ensure that protections did not inadvertently adversely affect pharmaceutical research.
16	Lobbying Issues	H.R.698, Prescription Reimportation, Improvement, Correction, and Enhancement Act, Lobbied to ensure that this bill does not undermine U.S. protections for American consumers from unsafe and ineffective counterfeit, expired or adulterated pharmaceutical products.
16	Lobbying Issues	H.R.91, Social Security On-line Privacy Protection Act, Lobbied to ensure that proposed privacy protections did not inadvertently restrict the use of protected clinical data in pharmaceutical research.
16	Lobbying Issues	S.1215, An original bill making appropriations for the Departments of Commerce, Justice, and State, the Judiciary and related agencies for the fiscal year ending September 30, 2002, and for other purposes., Lobbied to ensure that any proposed funding for the control and restriction of methamphetamine production did not inadvertently impede the use of ephedrine in over-the-counter (OTC) allergy pharmaceuticals.
16	Lobbying Issues	S.1628, Agriculture, Conservation, and Rural Enhancement Act of 2001, Monitored legislation affecting the sales of dietary supplements.
16	Lobbying Issues	S.318, Genetic Nondiscrimination in Health Insurance and Employment Act, Lobbied to ensure that protections did not inadvertently adversely affect pharmaceutical research.
16	Lobbying Issues	S.847, A bill to impose tariff-rate quotas on certain casein and milk protein concentrates., Lobbied to ensure that any proposed tariffs did not inadvertently impede the legitimate importation of caseins for use in baby formulas.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code ECN (one per page)

16. Specific Lobbying issues

H.R.2550, Economic Revitalization Tax Act of 2001, Support the passage of legislation to provide new economic incentives for investment in Puerto Rico and the U.S. possessions.

***Support the introduction of legislation to provide new economic incentives for investment in Puerto Rico and possessions.**

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code ENV (one per page)

16. Specific Lobbying issues
No activity.

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code FOR (one per page)

16. Specific Lobbying issues

Discussed the AIDS crisis in southern Africa and ways to increase funds in Africa via the tax code.

Provided guidelines for US Government's plan to develop global HIV/AIDS fund.

Advocated changing the agenda of a scheduled WHO Conference on differential pricing, access to medicines developing countries.

Lobbied to prevent the undermining of the WTO TRIPs agreement in the run-up to the WTO Ministerial Conference in Doha, Qatar.

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services

Department of State

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Thompson, Richard	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code GOV (one per page)
- 16. Specific Lobbying issues
S.754, Drug Competition Act of 2001, Lobbied for improved definitions section.

- 17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	
Thompson, Richard	

- 19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific Lobbying issues

H.CON.RES.83, Establishing the congressional budget for the United States Government for fiscal year 2002 congressional budget for the United States Government for fiscal year 2001, and setting forth appropriate budget levels for each of fiscal years 2, Lobbied for access to Rx medicines for seniors.

H.R.113, Wireless Telephone Spam Protection Act, Lobbied to ensure that protections did not advertently restrict the use of protected clinical data in pharmaceutical research.

H.R.1387, Drug Availability and Health Care Access Improvement Act of 2001, Lobbied for access to medicines for seniors.

H.R.1400, Prescription Drug Fairness for Seniors Act of 2001, Lobbied for access to medicines for seniors.

H.R.1644, Human Cloning Prohibition Act of 2001, Lobbied to ensure that any proposed restrictions did not inadvertently impede the use of stem cells and other research techniques in the discovery and development of pharmaceuticals.

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services

Department of State

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	
Ryan, John	
Thompson, Richard	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.1786, To impose tariff-rate quotas on certain casein and milk protein concentrates., Lobbied to ensure that any proposed tariffs did not inadvertently impede the legitimate importation of caseins for use in baby formulas.
16	Lobbying Issues	H.R.1866, To amend title 35, United States Code, to clarify the basis for grant requests for reexamination of patents., Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.1886, To amend title 35, United States Code, to provide for appeals by third parties in certain patent reexamination proceedings., Lobbied to ensure that proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.2047, Patent and Trademark Office Authorization Act of 2002, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.2172, Cloning Prohibition Act of 2001, Lobbied to ensure that any proposed restrictions did not inadvertently impede the use of stem cells and other research techniques in the discovery and development of pharmaceuticals.
16	Lobbying Issues	H.R.2315, Patients' Bill of Rights Act of 2001, Lobbied for greater access to prescription medicines.
16	Lobbying Issues	H.R.2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2002, Lobbied for increased patient safety requirements.
16	Lobbying Issues	H.R.2352, Fair Balance Prescription Drug Advertisement Act of 2001, Lobbied to ensure that any proposed restrictions did not inadvertently impede the consumer access to accurate information about pharmaceuticals.
16	Lobbying Issues	H.R.237, Consumer Internet Privacy Enhancement Act, Lobbied to ensure that any proposed privacy protections did not inadvertently restrict the use of protected clinical data in pharmaceutical research.
16	Lobbying Issues	H.R.2500, Departments of Commerce, Justice, and State, the Judiciary, and Related Agencies Appropriations., Lobbied to ensure that any proposed restrictions on methamphetamine production did not inadvertently impede the production of ephedrine in over-the-counter (OTC) allergy pharmaceuticals.
16	Lobbying Issues	H.R.2505, Human Cloning Prohibition Act of 2001, Lobbied to ensure that any proposed restrictions did not inadvertently impede the use of stem cells and other research techniques in the discovery and development of pharmaceuticals.
16	Lobbying Issues	H.R.2581, Export Administration Act of 2001, Lobbied to ensure that legislation does not adversely affect the ability to conduct legitimate clinical trials.
16	Lobbying Issues	H.R.260, Wireless Privacy Protection Act of 2001, Lobbied to ensure that protections did not inadvertently adversely restrict the use of protected clinical data in pharmaceutical research.
16	Lobbying Issues	H.R.2871, Export-Import Bank Reauthorization Act of 2001, Lobbied to ensure that legislation does not adversely undermine Intellectual Property rights.
16	Lobbying Issues	H.R.3061, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2002, Lobbied to ensure that NIH obtains sufficient funding to carry out its responsibilities.
16	Lobbying Issues	H.R.318, Commuter Benefit Equity Act of 2001, Lobbied to ensure that protections did not inadvertently adversely restrict the use of protected clinical data in pharmaceutical research.
16	Lobbying Issues	H.R.339, Medicare Outpatient Prescription Drug Coverage Act of 2001, Lobbied for access to medicines for seniors
16	Lobbying Issues	H.R.383, To amend the Internal Revenue Code of 1986 to allow a deduction for amounts paid for health insurance and prescription drug costs of individuals. Lobbied for access to medicines for seniors
16	Lobbying Issues	H.R.526, Bipartisan Patient Protection Act of 2001, Lobbied for greater access to prescription medicines.
16	Lobbying Issues	H.R.58, Medicine Equity and Drug Safety Act Corrections of 2001, Lobbied for increased patient safety requirements.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	H.R.602, Genetic Nondiscrimination in Health Insurance and Employment Act, Lobbied to ensure that protections did not advertently adversely affect pharmaceutical research.
16	Lobbying Issues	H.R.698, Prescription Reimportation, Improvement, Correction, and Enhancement Act, Lobbied to ensure that this bill does not undermine U.S. protections for American Consumers from unsafe and ineffective counterfeit, expired or adulterated pharmaceutical products.
16	Lobbying Issues	H.R.740, Patent and Trademark Office Reauthorization Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.741, Madrid Protocol Implementation Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.91, Social Security On-line Privacy Protection Act, Lobbied to ensure that protections did not advertently adversely restrict the use of protected clinical information in pharmaceutical research.
16	Lobbying Issues	H.R.933, Affordable HIV/AIDS Medicines for Poor Countries Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.10, Medicare Prescription Drug Coverage Act of 2001, Lobbied access to medicines for seniors.
16	Lobbying Issues	S.1052, Bipartisan Patient Protection Act, Lobbied for greater access to prescription medicines.
16	Lobbying Issues	S.1135, Medicare Reform Act of 2001, Lobbied for access to medicines for seniors.
16	Lobbying Issues	S.1215, An original bill making appropriations for the Departments of Commerce, Justice and the State, the Judiciary, and related agencies for the fiscal year ending September 30, 2002, and for other purposes, Lobbied to ensure that proposed funding for the control and restriction of methamphetamine production did not inadvertently impede the use of ephedrine in over-the-counter (OTC) allergy pharmaceuticals.
16	Lobbying Issues	S.125, Prescription Drug Fairness for Seniors Act of 2001, Lobbied for access to medicines for seniors.
16	Lobbying Issues	S.149, Export Administration Act of 2001, Lobbied to ensure that the legislation does not adversely affect the ability to conduct legitimate clinical trials.
16	Lobbying Issues	S.186, Generic Pharmaceutical Access and Choice for Consumers Act of 2001, Lobbied for access to medicines for seniors.
16	Lobbying Issues	S.197, Spyware Control and Privacy Protection Act of 2001, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.215, Medication Equity and Drug Savings Act, Lobbied for increased patient safety requirements.
16	Lobbying Issues	S.283, Bipartisan Patient Protection Act of 2001, Lobbied for greater access to prescription medicines.
16	Lobbying Issues	S.290, Student Privacy Protection Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.30, Financial Information Privacy Protection Act of 2001, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.318, Genetic Nondiscrimination in Health Insurance and Employment Act, Lobbied to ensure that protections did not inadvertently adversely affect pharmaceutical research.
16	Lobbying Issues	S.320, Intellectual Property and High Technology Technical Amendments Act of 2001, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.357, Medicare Preservation and Improvement Act of 2001, Lobbied for access to medicines for seniors.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

Item	Description	Data
16	Lobbying Issues	S.463, Global Access to AIDS Treatment Act of 2001, Lobbied to ensure that proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.6, Patients' Bill of Rights Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.847, A bill to impose tariff-rate quotas on certain casein and milk protein concentrates., Lobbied to ensure that any proposed tariffs did not inadvertently impede the legitimate importation of caseins for use in baby formulas.
16	Lobbying Issues	S.889, Bipartisan Patients' Bill of Rights Act of 2001, Lobbied for greater access to prescription medicines.
16	Lobbying Issues	*Discussed the AIDS crisis in southern Africa and ways to increase funds to Africa via the tax code. *Provided guidelines for US Government's plan to develop global HIV/AIDS. *Advocated changing the agenda of a scheduled WHO Conference on differential pricing, access to medicines in developing countries.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code INS (one per page)

16. Specific Lobbying issues

S.6, Patients' Bill of Rights Act, Lobbied to ensure that any proposed legislative provisions do not undermine pharmaceutical industry's ability to provide adequate health insurance for its employees.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code LAW (one per page)

16. Specific Lobbying issues

H.R.2341, Class Action Fairness Act of 2001, Lobbied to ensure fair treatment of class action law suits.
S.1712, Class Action Fairness Act of 2001, Lobbied to ensure fair treatment of class action law suits.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code LBR (one per page)

16. Specific Lobbying issues
No activity.

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific Lobbying issues

H.R.113, Wireless Telephone Spam Protection Act, Lobbied to ensure that any proposed privacy restrictions inadvertently restrict the use of protected clinical data in pharmaceutical research.

H.R.1644, Human Cloning Prohibition Act of 2001, Lobbied to ensure that any proposed restrictions did not inadvertently impede the use of stem cells and other research techniques in the discovery and development pharmaceuticals.

H.R.2172, Cloning Prohibition Act of 2001, Lobbied to ensure that any proposed restrictions did not inadvertently impede the use of stem cells and other research techniques in the discovery and development pharmaceutical

H.R.237, Consumer Internet Privacy Enhancement Act, Lobbied to ensure that any proposed privacy restrictions inadvertently restrict the use of protected clinical data in pharmaceutical research.

H.R.260, Wireless Privacy Protection Act of 2001, Lobbied to ensure that any proposed privacy restrictions inadvertently restrict the use of protected clinical data in pharmaceutical research.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.2505, Human Cloning Prohibition Act of 2001, Lobbied to ensure that a proposed restrictions did not inadvertently impede the use of stem cells and c research techniques in the discovery and development pharmaceuticals.
16	Lobbying Issues	H.R.602, Genetic Nondiscrimination in Health Insurance and Employment A Lobbied to ensure that protections did not inadvertently adversely affect pharmaceutical research.
16	Lobbying Issues	H.R.91, Social Security On-line Privacy Protection Act, Lobbied to ensure th protections did not advertently adversely restrict the use of protected clinical in pharmaceutical research.
16	Lobbying Issues	S.318, Genetic Nondiscrimination in Health Insurance and Employment Act, Lobbied to ensure that protections did not inadvertently adversely affect pharmaceutical research.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific Lobbying issues

H.CON.RES.83, Establishing the congressional budget for the United States Government for fiscal year 2002 congressional budget for the United States Government for fiscal year 2001, and setting forth appropriate budget levels for each of fiscal years 2, Lobbied for access to Rx medicines for seniors.

H.R.1387, Drug Availability and Health Care Access Improvement Act of 2001, Lobbied for access to medicines for seniors.

H.R.1400, Prescription Drug Fairness for Seniors Act of 2001, Lobbied for access to medicines for seniors.

H.R.1624, Access to Cancer Therapies Act of 2001, Lobbied for improved coverage of cancer drugs in Medicare.

H.R.339, Medicare Outpatient Prescription Drug Coverage Act of 2001, Lobbied for access to medicines for seniors.

H.R.383, To amend the Internal Revenue Code of 1986 to allow a deduction for amounts paid for health insurance prescription drug costs of individuals., Lobbied for access to medicines for seniors.

S.10, Medicare Prescription Drug Coverage Act of 2001, Lobbied for access to medicines for seniors.

17. House(s) of Congress and Federal agencies contacted Check if None

Department of Health & Human Services

House of Representatives

Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	
Ryan, John	
Thompson, Richard	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	S.1135, Medicare Reform Act of 2001, Lobbied for access to medicines for seniors.
16	Lobbying Issues	S.125, Prescription Drug Fairness for Seniors Act of 2001, Lobbied for access to medicines for seniors.
16	Lobbying Issues	S.186, Generic Pharmaceutical Access and Choice for Consumers Act of 2001, Lobbied for access to medicines for seniors.
16	Lobbying Issues	S.357, Medicare Preservation and Improvement Act of 2001, Lobbied for access to medicines for seniors.
16	Lobbying Issues	S.913, Access to Cancer Therapies Act of 2001, Lobbied for improved coverage of cancer drugs in Medicare.
16	Lobbying Issues	Lobbied for delays in the implementation of the Medicare Hospital Outpatient Department Prospective Payment System.



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code PHA (one per page)

16. Specific Lobbying issues
No activity.

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Carozza, Michael	
Keaney, David	
Ryan, John	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TAX (one per page)

16. Specific Lobbying issues

H.R.2550, Economic Revitalization Tax Act of 2001, Lobbied to ensure new economic incentives for investment in Puerto Rico and the U.S.

S.1475, Economic Revitalization Tax Act of 2001, Lobbied to ensure new economic incentives for investment in Puerto Rico and the U.S.

***Discussed the AIDS crisis in southern Africa and ways to increase funds to Africa via the tax code.**

17. House(s) of Congress and Federal agencies contacted Check if None
House of Representatives
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Ryan, John	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TEC (one per page)

16. Specific Lobbying issues

H.R.113, Wireless Telephone Spam Protection Act, Lobbied to ensure that any proposed privacy protections inadvertently restrict the use of protected clinical data in pharmaceutical research.

H.R.260, Wireless Privacy Protection Act of 2001, Lobbied to ensure that any proposed privacy protections inadvertently restrict the use of protected clinical data in pharmaceutical research.

17. House(s) of Congress and Federal agencies contacted Check if None

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: Bristol-Myers Squibb Company

Client Name: Self

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code TRD (one per page)

16. Specific Lobbying issues

H.R.1786, To impose tariff-rate quotas on certain casein and milk protein concentrates., Lobbied to ensure that proposed tariffs did not inadvertently impede the legitimate importation of caseins for use in baby formulas.

H.R.1866, To amend title 35, United States Code, to clarify the basis for granting requests for reexamination. Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.

H.R.1886, To amend title 35, United States Code, to provide for appeals by third parties in certain patent reexamination proceedings., Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical intellectual property rights.

H.R.2047, Patent and Trademark Office Authorization Act of 2002, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.

17. House(s) of Congress and Federal agencies contacted Check if None

**Department of Commerce
Department of Health & Human Services
House of Representatives
Office of U.S. Trade Representative
Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Keaney, David	
Warr, David	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature _____ Date 2/13/2002



Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Item	Description	Data
16	Lobbying Issues	H.R.740, Patent and Trademark Office Reauthorization Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.741, Madrid Protocol Implementation Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	H.R.933, Affordable HIV/AIDS Medicines for Poor Countries Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.197, Spyware Control and Privacy Protection Act of 2001, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.290, Student Privacy Protection Act, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.30, Financial Information Privacy Protection Act of 2001, Lobbied to ensure any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.320, Intellectual Property and High Technology Technical Amendments Act of 2001, Lobbied to ensure that any proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.463, Global Access to AIDS Treatment Act of 2001, Lobbied to ensure that proposed legislative provisions do not undermine the pharmaceutical industry's intellectual property rights.
16	Lobbying Issues	S.847, A bill to impose tariff-rate quotas on certain casein and milk protein concentrates., Lobbied to ensure that any proposed tariffs did not inadvertently impede the legitimate importation of caseins for use in baby formulas.
16	Lobbying Issues	*Discussed the update to the GATT Pharmaceutical Appendix, (allows for all newly developed compounds to become duty free).
		*Discussed Intellectual Property Rights issues, specifically related to the Special 301 List.
		*Advocated changing the agenda of a scheduled WHO Conference on differential pricing, access to medicines in developing countries.



Registrant Name: **Bristol-Myers Squibb Company**

Client Name: **Self**

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

21. Client new principal place of business (if different from line 20)

City _____ State/Zip (or Country) _____

22. New general description of client's business or activities

Pharmaceutical Research & Development

LOBBYIST UPDATE

23. Name of each previously reported individual who is **no longer** expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that **no longer** pertain

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Name	Address	Principal Place of Business (city and state or country)


26. Name of each previously reported organization that is **no longer** affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

Name	Address	Principal Place of Business (city and state or country)	Amount of contribution for lobbying activities

28. Name of each previously reported foreign entity that **no longer** owns, or controls, or is affiliated with the registrant or affiliated organization

Signature  Date 2/13/2002

